PO.MCB07.02 · 分子与细胞生物学
一个基因组缺失变异体控制超级增强子驱动的LINC00636和CD47过表达以促进乳腺癌肿瘤细胞存活
A genomic deletion variant controls super-enhancer-driven overexpression of LINC00636 and CD47 to promote tumor cell survival in breast cancer
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
癌症中基因表达失调常由超级增强子(SE)等非编码区的表观遗传重编程所驱动。这些大型增强子簇在正常组织中很少活跃,但可驱动促进恶性特征(包括免疫逃逸)的基因过表达。此前我们已经证明,SE与三阴性乳腺癌(TNBC)中的化疗耐药和抗凋亡基因表达相关。尽管SE是有前景的治疗靶点,但其庞大的体积使其难以在癌症治疗中被有效靶向。这一局限凸显了识别SE内更小、功能关键的区域作为精确治疗切入点的必要性。本研究的目标是界定并功能性验证乳腺癌特异性SE内对于驱动免疫逃逸所必需且充分的核心元件。我们假设这些核心元件单独或联合作用,通过异常激活免疫抑制基因CD47和调控性长非编码RNA LINC00636,充当恶性肿瘤的分子驱动因素。我们的理论依据源于发现一个乳腺癌特异性SE,该SE含有一个调控CD47和LINC00636表达的种系插入/缺失(InDel)变异体。在工程化乳腺癌细胞中CRISPR缺失该变异体增加了SE区域的染色质可及性,导致CD47和LINC00636上调、对营养剥夺诱导的凋亡的抗性增强(通过CD47)、衰老激活(由LINC00636升高所驱动)以及细胞死亡延迟。对缺乏插入的细胞和高LINC00636表达的细胞进行的RNA-seq分析揭示了共同的免疫抑制和促存活转录程序,包括CXCL17、STAT1、CXCL8和ANGPTL4的升高——这些基因与肿瘤免疫信号传导、衰老和凋亡抗性相关。在具备巨噬细胞功能的异种移植模型中,缺失该变异体减少了抗肿瘤巨噬细胞浸润,支持免疫逃逸状态的激活。在临床上,携带插入等位基因的乳腺癌患者与缺失纯合子患者相比表现出改善的无进展生存期——证明了离散SE元件的临床相关性。总之,我们的发现将一个常见的InDel变异体确定为一个微小核心元件,它微调控制CD47和LINC00636的双功能SE的调控活性。我们的工作为乳腺癌中SE介导的基因失调提供了新见解,并凸显了靶向离散SE组分而非整个增强子簇的治疗潜力。
查看英文原文 English abstract
Dysregulated gene expression in cancer is often driven by epigenetic reprogramming of non-coding regions such as super-enhancers (SEs). These large enhancer clusters are rarely active in normal tissues but can drive overexpression of genes that promote malignant traits, including immune evasion. Previously we have shown that SEs are linked to chemotherapy resistance and anti-apoptotic gene expression in triple-negative breast cancer (TNBC). Although SEs are promising therapeutic targets, their large size makes them difficult to target effectively in cancer therapy. This limitation underscores the need to identify smaller, functionally critical regions within SEs that can serve as precise therapeutic entry points.The goal of this research is to define and functionally validate core elements within breast cancer-specific SEs that are necessary and sufficient to drive immune escape. We hypothesize that these core elements, alone or in combination, act as molecular drivers of malignancy by aberrantly activating the immune-suppressive gene CD47 and the regulatory long non-coding RNA LINC00636 .Our rationale stems from the discovery of a breast cancer-specific SE harboring a germline insertion/deletion (InDel) variant that regulates CD47 and LINC00636 expression. CRISPR deletion of this variant in engineered breast cancer cells increased chromatin accessibility of the SE region, leading to upregulation of CD47 and LINC00636 , enhanced resistance to nutrient-deprivation-induced apoptosis (via CD47 ), activation of senescence (driven by elevated LINC00636 ), and delayed cell death. RNA-seq analyses of cells lacking the insertion and cells with high LINC00636 expression revealed a shared immunosuppressive and pro-survival transcriptional program, including increased CXCL17, STAT1, CXCL8 , and ANGPTL4 -genes associated with tumor immune signaling, senescence and apoptosis resistance. In macrophage-competent xenograft models, deletion of the variant reduced anti-tumor macrophage infiltration, supporting activation of an immune-evasive state. Clinically, breast cancer patients carrying the insertion allele show improved progression-free survival when compared to patients homozygous for the deletion-demonstrating the clinical relevance of discrete SE elements.Together, our findings identify a common InDel variant as a minimal core element that fine-tunes the regulatory activity of a bifunctional SE controlling CD47 and LINC00636 . Our work provides new insight into SE-mediated gene dysregulation in breast cancer and highlights the therapeutic potential of targeting discrete SE components rather than entire enhancer clusters.
利益披露 Disclosure
C. Di Benedetto, None..
A. Tsark, None..
A. Thach, None..
A. Singhal, None..
A. Rodriguez, None..
P. Betancur, None.